BioNTech SE (NASDAQ:BNTX) Given Consensus Rating of “Moderate Buy” by Brokerages

BioNTech SE (NASDAQ:BNTX) has been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $137.54.

Several equities research analysts have weighed in on the stock. HSBC increased their target price on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft lifted their target price on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. UBS Group increased their price target on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. HC Wainwright lifted their price objective on BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a report on Monday, October 7th. Finally, JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a report on Monday, November 4th.

BioNTech Stock Up 2.6 %

Shares of BioNTech stock opened at $110.64 on Friday. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The business has a fifty day simple moving average of $111.85 and a 200 day simple moving average of $96.55. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The stock has a market cap of $26.31 billion, a PE ratio of -52.69 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.34% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the prior year, the business posted $0.73 EPS. BioNTech’s revenue was up 38.9% on a year-over-year basis. Research analysts predict that BioNTech will post -2.93 EPS for the current year.

Institutional Trading of BioNTech

A number of hedge funds and other institutional investors have recently modified their holdings of BNTX. Covestor Ltd boosted its position in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the last quarter. Planning Capital Management Corp boosted its holdings in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after buying an additional 450 shares during the last quarter. Blue Trust Inc. grew its stake in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after acquiring an additional 238 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.